IVIEW Therapeutics Inc. is a clinical-stage ophthalmology-focused therapeutics company based in Cranbury, New Jersey committed to the treatment of ocular diseases with high unmet medical needs through innovative small molecule drugs and gene therapy approaches. Our focus on novel mechanisms of action combined with our proprietary drug delivery technology platforms allows us to advance highly differentiated assets with superior target product profiles. Currently, our portfolio includes novel products to treat Acute Infectious Conjunctivitis, Dry Eye Disease (DED) and Glaucoma. IVIEW has built an exceptional team with ophthalmologists and pharmaceutical experts with entrepreneurial experience to execute on its drug development programs. IVIEW’s strategy has been externally validated with an investment of over $40M from well-known VCs. We are seeking development/commercialization partners and in parallel pursuing an additional Series B fundraising round with a target raise of $30M.